Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

Late-breaking Phase 3 data at AAD 2022 show Dupixent® significantly improved signs and symptoms of prurigo nodularis Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly three... | March 26, 2022

Related Keywords

Japan ,United States ,Paris ,France General ,France ,American ,Eva Schaefer Jansen ,Corentine Driancourt ,Gil Yosipovitch ,Felix Lauscher ,Vesna Tosic ,Hannah Kwagh ,Nathalie Pham ,Sally Bain ,Priya Nanduri ,Regeneron Pharmaceuticals Inc ,Twitter ,Regeneron Genetics Center ,Dupilumab Development Program ,Nasdaq ,Teva Pharmaceutical Industries Ltd ,Exchange Commission ,American Academy Of Dermatology ,University Of Miami ,Miller School Of Medicine ,Euronext ,Globenewswire Inc ,Late Breaking Phase ,Worst Itch Numeric Rating Scale ,Global Assessment ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Teva Pharmaceutical Industries ,Sanofi Stock Exchange ,News ,Information ,Press Release ,Hase , ,Data ,It ,Sad ,022 ,Show ,Ignificantly ,Mproved ,Signs ,End ,Symptoms ,F ,Prurigo ,Nodularis ,Dupixent ,Educed ,Pitch ,2 ,4 ,Eeks ,Early San Fr0000120578 ,